论文信息 - In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer. - 字舞流文

In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.

F. Yakes | A. Joly | Lora Zhao | V. Vysotskaia | Wentao Zhang | P. Lamb | S. Engst | Yongchang Shi | L. Goon | Felix Chu | P. Yu | F. Bentzien | M. Zuzow | B. Cancilla | R. Bautista | Donghui Huang | N. Heald | A. Gibson | Leanne H. Goon | Alison H. Joly